Vadadustat

Vadadustat (INN; AKB-6548) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia secondary to chronic kidney disease.[1][2][3]

Vadadustat

Clinical data
Other names	AKB-6548, PG-1016548
ATC code	None
Identifiers
IUPAC name 2-([5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino)acetic acid
CAS Number	1000025-07-9
PubChem CID	23634441
ChemSpider	34958379
UNII	I60W9520VV
KEGG	D11078
ECHA InfoCard	100.248.991
Chemical and physical data
Formula	C14H11ClN2O4
Molar mass	306.70 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Oc1cc(cnc1C(=O)NCC(=O)O)c2cccc(Cl)c2

See also

• Daprodustat
• Desidustat
• Molidustat
• Roxadustat

References

1. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH (November 2016). "Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease". Kidney International. 90 (5): 1115–1122. doi:10.1016/j.kint.2016.07.019. PMID 27650732.
2. Gupta N, Wish JB (June 2017). "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD". American Journal of Kidney Diseases. 69 (6): 815–826. doi:10.1053/j.ajkd.2016.12.011. PMID 28242135.
3. Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM (2017). "Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease". American Journal of Nephrology. 45 (5): 380–388. doi:10.1159/000464476. PMC 5452283. PMID 28343225.